Synthace

Executive Summary

Synthace is a UK-based software company that accelerates discovery biology in life sciences through a platform combining digital experiment design, automation orchestration, and data analysis. Founded in 2011 and headquartered in London, the company serves drug discovery and synthetic biology teams in biopharma and related industries. By enabling multivariate experiments that are more efficient and insightful, Synthace helps researchers uncover complex biological relationships faster and with higher reproducibility. The platform integrates with existing lab automation hardware and data systems, reducing manual effort and improving data quality. As the biopharma industry increasingly adopts AI and automation to shorten R&D cycles, Synthace is well-positioned to become a critical infrastructure layer for R&D labs. The company's focus on the intersection of AI, synthetic biology, and digital health aligns with major industry trends toward data-driven experimentation and lab digitization. While the bootstrapped or venture-backed status is unclear, Synthace's long operating history suggests a degree of resilience. The company's continued relevance in a competitive landscape of ELN/LIMS and automation software depends on its ability to demonstrate return on investment through documented customer success and integrations with leading lab equipment vendors. Overall, Synthace addresses a clear need for more efficient experimental design in complex biological research, and its platform approach offers scalability across multiple therapeutic areas.

Upcoming Catalysts (preview)

• Q1 2026Major partnership with a top-20 pharma company for platform deployment60% success
• Q2 2026Release of new AI-driven experimental design module70% success
• Q3 2026Series B funding round led by prominent life sciences VC50% success